=== PAGE 6 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Colleen Matkowski
Aclaris Therapeutics, Inc.
NDA 209305/MA 56

                                                                                                       Page 6

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Eskata comply with each
applicable requirement of the FD&C Act and FDA implementing regulations.


                                                                                       Sincerely,

                                                                        {See appended electronic signature page}

                                                                        Laurie Buonaccorsi, Pharm.D.
                                                                        Regulatory Review Officer
                                                                        Division of Advertising & Promotion Review 2
                                                                        Office of Prescription Drug Promotion


                                                                        Matthew J. Falter, Pharm.D.
                                                                        Team Leader
                                                                        Division of Advertising & Promotion Review 2
                                                                        Office of Prescription Drug Promotion






Reference ID: 4449083
